Nonpartisan civic infrastructure
AllCiv·Legis1
·

H.R. 965

BillFederalHouseIn Committee
To promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products.
About This Bill
Committee
Latest Action · May 16, 2019
Supplemental report filed by the Committee on the Judiciary, H. Rept. 116-55, Part III.
Introduced
February 5, 2019
Cosponsors (68)
55D 13R
View PDF ↗
SummaryFull TextCommentsAnnotations

Public Comments (0)

No comments yet. Be the first to weigh in from the Take Action box.

Take Action

Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.